Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 
 

Merck KGaA, Darmstadt, Germany, raises earnings guidance for full year 2013 after a successful third quarter

  • Solid organic sales growth continues in the third quarter
  • Significant 10% increase of EBITDA pre one-time effects
  • Earnings per share pre one-time items increase to a record € 2.29 in the third quarter
  • Full-year EBITDA pre one-time effects guidance for 2013 raised to about € 3.2 - 3.25 billion
 

Publication of business results for Q3 2013

"This repeatedly strong result illustrates once again that we are on track with the transformation of our company. We are already stronger today and more profitable than when we started the change process a few years ago,“ said Karl-Ludwig Kley, Chairman of the Executive Board of Merck KGaA, Darmstadt, Germany. In the third quarter 2013 our company continued his solid business performance in a challenging market environment.
The pharmaceutical, chemical and life science company posted solid organic revenue growth of 4.7%. EBITDA pre one-time items increased significantly by 10% in spite of headwinds from foreign exchange effects so that the guidance could be increased to a range between about € 3.2 billion and € 3.25 billion.
On this site we have bundled all information as well as relevant links regarding our third-quarter 2013 earnings. In addition to the online report, you will find the press release, analyst presentation and pictures.

PRESS KIT

Press Kit
In this Zip file you will find all relevant documents.

ADDITIONAL INFORMATION

Publication of business results for Q3 2013
Here you will find detailed information from the financial report Q3 2013.

CONTACT

Gangolf Schrimpf
Gangolf Schrimpf
Tel: +49 6151 72 9591
Fax: +49 6151 72-7707
E-Mail

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.